ALK and melanoma: Additionally, vemurafenib-resistant melanoma cells-derived EVs could increase the proliferation of sensitive cells during vemurafenib therapy compared to the control cells via transporting an ALK isoform (truncated ALK fused with murine leukemia virus (MMLV)) [56].